Opthea (OPT) announced the publication of sozinibercept Phase 2b data in the peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina. The paper entitled “Sozinibercept Combination Therapy for Neovascular Age-Related Macular Degeneration: Phase 2b Study Subgroup Analysis by Lesion Type” reports pre-specified and post-hoc analyses of angiographic predictors of response to sozinibercept combination therapy with ranibizumab in treatment-naive patients with wet AMD. The Phase 2b pre-specified analyses of subgroups showed that in patients with occult and minimally classic lesions excluding RAP, which represented 73% of the Phase 2b total patient population, sozinibercept combination therapy demonstrated a statistically significant additional 5.7 letter mean gain in best corrected visual acuity compared to ranibizumab alone
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPT:
- Opthea Limited Reports Increased Losses Amid Clinical Advancements
- Opthea reports 1H adjusted EPS ($5.73) vs. ($14.25) last year
- Opthea announces anticipated milestones
- Optimistic Buy Rating for Opthea Limited Driven by Promising Phase 3 Trials and Innovative AMD Treatment
- Opthea completes drug product PPQ campaign